Additionally, Gal-9 decreases signaling from key receptors, including the Epidermal Growth Factor Receptor, the Insulin-like Growth Factor-1 Receptor, the Hepatocyte Growth Factor Receptor, and the Fibroblast Growth Factor Receptor 3 in CCA, resulting in reduced tumor size in CCA cell lines and animal models. Here, MET is linked to cholangiocarcinoma.